Literature DB >> 12222751

Decreased hepatic drug metabolising enzyme activity in rats with nitrosamine-induced tumours.

P P Maliakal1, P F Coville, S Wanwimolruk.   

Abstract

N-Methyl N-benzyl nitrosamine (MBNA), which requires P450-dependant activation to be mutagenic, has been shown to produce squamous cell carcinoma of rat oesophagus. The aim of this study was to determine the effects of tumour induction on hepatic cytochrome P450 (CYP) and phase II enzyme activity. Female Wistar rats were given MBNA (2.5 mg/kg) by gavage, twice weekly for 12 weeks. At the end of 12 weeks they were sacrificed; livers and oesophagi were removed. The activity of hepatic CYP and phase II enzymes was determined by incubation of liver microsomes with appropriate CYP substrates. All rats receiving MBNA developed oesophageal lesions. Hepatic CYP1A2 activity (phenacetin 5 microM) in tumour-bearing rats was significantly decreased to 53% of the controls (p <0.05). CYP2E1 (p-nitrophenol hydroxylase), CYP2D (debrisoquine hydroxylase) and CYP3A (quinine hydroxylase) activity was significantly (p <0.05) reduced. Microsomal UDP-glucuronosyl transferase activity was also found to be markedly decreased while glutathione-S-transferase activity remained almost unchanged. Alteration of the activities of drug metabolising enzymes in rats with chemically induced tumours could be an important factor in determining resistance or susceptibility to xenobiotics and antitumour drugs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12222751     DOI: 10.1515/dmdi.2002.19.1.13

Source DB:  PubMed          Journal:  Drug Metabol Drug Interact        ISSN: 0792-5077


  1 in total

1.  Phase I/II enzyme gene polymorphisms and esophageal cancer risk: a meta-analysis of the literature.

Authors:  Chun-Xia Yang; Keitaro Matsuo; Zhi-Ming Wang; Kazuo Tajima
Journal:  World J Gastroenterol       Date:  2005-05-07       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.